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Background
Trastuzumab improves survival in the adjuvant treatment of HER-positive breast 
cancer, although combined therapy with anthracycline-based regimens has been 
associated with cardiac toxicity. We wanted to evaluate the efficacy and safety of a 
new nonanthracycline regimen with trastuzumab.
Methods
We randomly assigned 3222 women with HER2-positive early-stage breast cancer to 
receive doxorubicin and cyclophosphamide followed by docetaxel every 3 weeks (AC-T), 
the same regimen plus 52 weeks of trastuzumab (AC-T plus trastuzumab), or docetaxel 
and carboplatin plus 52 weeks of trastuzumab (TCH). The primary study end point was 
disease-free survival. Secondary end points were overall survival and safety.
Results
At a median follow-up of 65 months, 656 events triggered this protocol-specified 
analysis. The estimated disease-free survival rates at 5 years were 75% among pa-
tients receiving AC-T, 84% among those receiving AC-T plus trastuzumab, and 81% 
among those receiving TCH. Estimated rates of overall survival were 87%, 92%, and 
91%, respectively. No significant differences in efficacy (disease-free or overall sur-
vival) were found between the two trastuzumab regimens, whereas both were su-
perior to AC-T. The rates of congestive heart failure and cardiac dysfunction were 
significantly higher in the group receiving AC-T plus trastuzumab than in the TCH 
group (P<0.001). Eight cases of acute leukemia were reported: seven in the groups 
receiving the anthracycline-based regimens and one in the TCH group subsequent 
to receiving an anthracycline outside the study.
Conclusions
The addition of 1 year of adjuvant trastuzumab significantly improved disease-free 
and overall survival among women with HER2-positive breast cancer. The risk–ben-
efit ratio favored the nonanthracycline TCH regimen over AC-T plus trastuzumab, 
given its similar efficacy, fewer acute toxic effects, and lower risks of cardiotoxicity 
and leukemia. (Funded by Sanofi-Aventis and Genentech; BCIRG-006 ClinicalTrials 
.gov number, NCT00021255.)
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T he her2 gene encodes a tyrosine kinase receptor that mediates critical sig-naling functions in normal and malignant 
breast epithelial cells.1 An acquired alteration con-
sisting of amplification and overexpression of the 
gene product occurs in approximately 20 to 25% 
of human breast cancers.2,3 HER2 overexpression 
is associated with an aggressive clinical pheno-
type that includes high-grade tumors, increased 
growth rates, early systemic metastasis, and de-
creased rates of disease-free and overall survival.2,3 
Preclinical data indicate that this adverse clinical 
picture results from fundamental changes in the 
biologic features of breast-cancer cells contain-
ing the alteration, including increased prolifera-
tion, suppression of apoptosis, increased motility, 
greater invasive and metastatic potential, accel-
erated angiogenesis, and steroid hormone inde-
pendence.4-11
In previous studies, many of these HER2-medi-
ated adverse characteristics were reversed by the 
use of monoclonal antibodies directed against the 
tyrosine kinase receptor,10,12-15 and these data led 
to phase 1 testing of a murine anti-HER2 mono-
clonal antibody, 4D5.16 Preliminary efficacy and 
safety data prompted the development of a hu-
manized monoclonal antibody to produce trastuz-
umab.17 Alone and in combination with chemo-
therapy, trastuzumab has been shown to have an 
acceptable safety record and to be active in ad-
vanced HER2-positive disease.18-20 Subsequently, 
in a large, randomized study, the addition of tras-
tuz umab to chemotherapy yielded significant im-
provements in rates of objective response, response 
duration, and time to disease progression (56%, 
58%, and 65% improvement, respectively), as well 
as a 30% improvement in the rate of overall sur-
vival among patients with first-line metastatic 
disease.21 A significant side effect was an in-
crease by a factor of 4 in the rate of cardiac dys-
function, including congestive heart failure, espe-
cially when trastuzumab was used in combination 
with anthracycline-based regimens.21
These data led to the initial regulatory ap-
proval of trastuzumab for metastatic HER2-posi-
tive breast cancer and resulted in its evaluation 
in early-stage disease. Five randomized trials (four 
large and one small) were then launched to evalu-
ate the efficacy and safety of adjuvant therapy with 
trastuzumab, and findings in three of these trials 
have been reported.22-24 One report contained re-
sults from similar treatment groups in two stud-
ies.23 All three large studies used trastuzumab in 
combination either exclusively or predominantly 
with anthracycline-based regimens,22,23 and all 
showed a significant benefit of trastuzumab, with 
a reduction in the rate of recurrence of approxi-
mately 50% and improvement in the rate of sur-
vival of approximately 30%.22,23 Again, an increase 
by a factor of 4 to 5 in the rate of congestive heart 
failure was noted when adjuvant trastuzumab 
was used with anthracyclines, and an even larger 
proportion of patients had subclinical loss of left 
ventricular function.22,23,25,26
In the fourth large study, the Breast Cancer 
International Research Group 006 (BCIRG-006) 
trial, we also evaluated adjuvant therapy with 
trastuzumab but included a second trastuzumab-
containing regimen, which did not have an anthra-
cycline. This new regimen, consisting of docetaxel, 
carboplatin, and trastuzumab (TCH), is based on 
preclinical synergies observed between trastuz-
umab and platinum salts or docetaxel that were 
not seen with anthracyclines or paclitaxel.14,27,28 
It was also anticipated that TCH might circum-
vent the cardiac toxicity seen with anthracycline-
based regimens.21 Phase 2 and 3 trials of TCH in 
patients with advanced disease showed that this 
regimen resulted in the longest period of pro-
gression-free survival reported to date, with rare 
cardiac dysfunction.18-20 A trial comparing TCH 
with docetaxel plus trastuzumab in metastatic 
disease showed no significant difference in pro-
gression-free survival between these two regi-
mens.29 However, the dose of docetaxel was 33% 
higher in the group receiving docetaxel plus tras-
tuzumab than in the group receiving TCH (100 mg 
per square meter of body-surface area vs. 75 mg 
per square meter). The only trial that directly evalu-
ated the added benefit of carboplatin in a dose-
equivalent, taxane-containing regimen showed 
that TCH had a significant advantage with re-
spect to progression-free survival over paclitaxel 
plus trastuzumab.19 For these reasons, we decid-
ed to evaluate TCH in addition to an anthracy-
cline-based regimen in adjuvant treatment of 
HER2-positive breast cancers. We report efficacy 
and safety results from this study in an intention-
to-treat analysis of data from all 3222 patients.
Me thods
Patients and Study Design
From April 2001 through March 2004, we random-
ly assigned 3222 women with HER2-positive, in-
vasive, high-risk, node-negative or node-positive 
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adenocarcinoma (stage T1, T2, or T3) from 41 
countries to receive a standard adjuvant anthracy-
cline–taxane chemotherapy regimen, the same 
regimen plus trastuzumab, or a new non-anthra-
cycline, trastuzumab-based regimen (Fig. 1 in the 
Supplementary Appendix, available with the full 
text of this article at NEJM.org). Specific demo-
graphic and clinical characteristics of patients were 
similar in the three study groups (Table 1). The 
HER2-positive status of all tumors was confirmed 
with the use of fluorescence in situ hybridization 
(PathVision, Abbott) before randomization.
In the first group, women received standard 
therapy with doxorubicin (60 mg per square me-
ter) and cyclophosphamide (600 mg per square 
meter) every 3 weeks for four cycles, followed by 
docetaxel (100 mg per square meter) every 3 weeks 
for four doses (AC-T). In the second group, pa-
tients received AC-T plus trastuzumab, beginning 
with the first dose of docetaxel and continuing 
for 1 year (AC-T plus trastuzumab). In the third 
group, patients received docetaxel (75 mg per 
square meter) plus carboplatin (area under the 
curve, 6 mg per milliliter per minute), given every 
3 weeks for six cycles concurrently with trastu-
zumab, followed by trastuzumab for an additional 
34 weeks (TCH). In the two trastuzumab-contain-
ing regimens, trastuzumab was initially admin-
istered at a dose of 4 mg per kilogram of body 
weight, followed by 2 mg per kilogram per week 
during chemotherapy and then 6 mg per kilogram 
every 3 weeks to complete 1 year of trastuzumab 
treatment. Hematopoietic growth factors were 
used at the discretion of treating physicians.
The institutional review board at each institu-
tion approved the study. All patients provided writ-
ten informed consent.
Primary and Secondary End Points
The study’s primary end point was disease-free sur-
vival, which was defined as the time from ran-
domization to breast-cancer recurrence, a second 
primary cancer (excluding contralateral ductal car-
cinoma in situ), or death from any cause, which-
ever came first. Secondary end points included 
overall survival, global safety, and cardiac safety.
Cardiac Safety
In addition to monitoring general safety, we in-
stituted an intense cardiac-monitoring schedule. 
We measured the left ventricular ejection fraction 
(LVEF) in each patient seven times throughout the 
study to detect congestive heart failure or sus-
tained asymptomatic subclinical loss of mean 
LVEF, which was defined as a relative reduction 
from baseline of more than 10% at the last fol-
low-up evaluation (Section 2 in the Supplementary 
Appendix). An independent cardiac review panel 
whose members were unaware of study-group 
assignments reviewed all cases of suspected car-
diac events. In addition, we calculated and report-
ed the mean LVEF in each study group, measured 
at protocol-defined times, along with 95% confi-
dence intervals.
TOP2A Coamplification
We also evaluated the effect on efficacy of a sec-
ond alteration within the HER2 amplicon that 
imparts incremental anthracycline sensitivity to 
a subset of HER2-positive cancers. The prespeci-
fied analysis of the gene encoding topoisomerase 
II alpha (TOP2A) showed that coamplification of 
this gene occurs in 35% of HER2-positive cancers. 
These data, together with the methods used, have 
been reported previously.30 When present, TOP2A 
coamplification is associated with the incremen-
Table 1. Baseline Characteristics of the Patients.*
Characteristic
AC-T
(N = 1073)
AC-T plus 
Trastuzumab
(N = 1074)
TCH
(N = 1075)
number of patients (percent)
Age <50 yr 562 (52) 559 (52) 577 (54)
Karnofsky performance score of 100† 856 (80) 853 (79) 862 (80)
Mastectomy 638 (59) 675 (63) 642 (60)
Radiotherapy 718 (67) 723 (67) 729 (68)
Hormonal therapy 531 (49) 542 (50) 541 (50)
No. of positive nodes
0 309 (29) 306 (28) 307 (29)
1 to 3 413 (38) 410 (38) 415 (39)
4 to 10 235 (22) 259 (24) 249 (23)
>10 116 (11) 99 (9) 104 (10)
Tumor size‡
≤2 cm 439 (41) 413 (38) 431 (40)
>2 to 5 cm 566 (53) 591 (55) 574 (53)
>5 cm 67 (6) 70 (7) 68 (6)
Positive for estrogen receptor, pro-
gesterone receptor, or both
576 (54) 578 (54) 579 (54)
* There were no significant differences among the three groups. AC-T denotes 
doxorubicin and cyclophosphamide followed by docetaxel, and TCH docetaxel, 
carboplatin, and trastuzumab.
† A Karnofsky score of 100 indicates no measurable loss of performance status.
‡ The tumor size was unavailable for one patient in the AC-T group and two 
 patients in the TCH group.
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tal benefit previously described for anthracycline 
as compared with nonanthracycline regimens in 
HER2-positive breast cancers.31,32
Study Oversight
The study was conducted in accordance with the 
protocol, which is available at NEJM.org. The breast 
steering committee of the BCIRG study group, 
which was composed entirely of academic inves-
tigators, designed the study and collected and ana-
lyzed all the data. The trial advisory committee 
consisted of one member from each sponsor and 
six members of the BCIRG breast steering com-
mittee. The resulting report was written by the 
first author and reviewed by the steering commit-
tee, who made the decision to submit the manu-
script for publication. All authors vouch for the 
accuracy and completeness of the data. The spon-
sor and major funder of the study was Sanofi-
Aventis, with additional support provided by Gen-
entech. Trastuzumab was provided by Genentech 
free of charge for study patients in the United States 
and was purchased by Sanofi-Aventis for all study 
patients in other countries. Docetaxel was pro-
vided by Sanofi-Aventis for all study patients.
Statistical Analysis
We used log-rank tests to compare disease-free sur-
vival and overall survival in the three study groups 
and plotted Kaplan–Meier product-limit estimators. 
We planned to conduct three protocol-specified in-
terim analyses and a final analysis after observing 
300, 450, 650, and 900 events, respectively, accord-
ing to an O’Brien–Fleming group sequential bound-
ary. The significance levels (alpha) for these anal-
yses were equal to approximately 0.0002, 0.0030, 
0.0111, and 0.0461, respectively. At each analysis, 
a step-down testing procedure was used. We com-
pared the AC-T group with each tras tuzumab-
containing regimen (AC-T plus tras tuzumab and 
TCH) at a significance level equal to one half alpha 
to account for multiple testing. If both compari-
sons were significant, we compared the two tras-
tuz umab regimens at a significance equal to alpha.
The first interim analysis was carried out after 
the observation of 322 disease-free survival events 
in September 2005. At that time, the efficacy 
boundaries were crossed and showed a signifi-
cant difference in disease-free survival events in 
favor of both AC-T plus trastuzumab and TCH, as 
compared with AC-T, with no significant differ-
ence between AC-T plus trastuzumab and TCH. 
Here, we present the results of the third protocol-
specified analysis. For this protocol-specified 
analy sis (656 events), the study had a power of 
80% to detect a hazard ratio of 0.75 or less for 
the comparison of either of the two trastuzumab-
containing regimens with AC-T and a power of 
75% to detect a hazard ratio of 0.64 or less for 
the comparison of AC-T plus trastuzumab with 
TCH. All reported P values are two-sided. All 
analyses were conducted by the International In-
stitute for Drug Development and were performed 
with the use of SAS statistical software, version 9.0 
(SAS Institute). The results of all analyses were 
presented to an independent data and safety moni-
toring committee.
R esult s
Primary and Secondary End Points
At the time of this analysis, 656 disease-free sur-
vival events were observed (257 in the group re-
ceiving AC-T, 185 in the group receiving AC-T plus 
trastuzumab, and 214 in the group receiving TCH). 
At this point, 348 patients had died during a me-
dian follow-up of 65 months. For both primary 
and secondary efficacy end points, a significant 
benefit with respect to disease-free and overall 
survival was seen in both groups treated with 
trastuzumab-containing regimens, as compared 
with the group that received AC-T (standard thera-
py), which had a 5-year rate of disease-free survival 
of 75% (Fig. 1A) and a rate of overall survival of 
87% (Fig. 2 in the Supplementary Appendix). For 
patients receiving AC-T plus tra stuzumab, the 5-year 
rate of disease-free survival was 84% (hazard ra-
tio for the comparison with AC-T, 0.64; P<0.001), 
and the rate of overall survival was 92% (hazard 
ratio, 0.63; P<0.001). For patients receiving TCH, 
the 5-year rate of disease-free survival was 81% 
(hazard ratio, 0.75; P = 0.04), and the rate of over-
all survival was 91% (hazard ratio, 0.77; P = 0.04). 
In contrast, no significant difference in the rate 
of disease-free or overall survival was seen be-
tween the two trastuzumab-containing regimens. 
However, the study was not powered to detect 
equivalence between these two regimens.
Analyses of absolute between-group differenc-
es, stratified according to nodal status and tumor 
size, were also performed. These analyses showed 
that among node-negative patients, the estimat-
ed rates of disease-free survival at 5 years were 
significantly improved by trastuzumab, with a rate 
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of 93% in the group receiving AC-T plus trastu-
zumab and 90% in the group receiving TCH, as 
compared with 85% in the group receiving AC-T 
(hazard ratio for AC-T plus trastuzumab, 0.47; 
P = 0.003; hazard ratio for TCH, 0.64; P = 0.06) 
(Table 1A in the Supplementary Appendix).
Among node-positive patients, trastuzumab 
also significantly improved 5-year rates of disease-
free survival, which were 80% in the group re-
ceiving AC-T plus trastuzumab and 78% in the 
group receiving TCH, as compared with 71% in 
the group receiving AC-T (hazard ratio for AC-T 
plus trastuzumab, 0.68; P<0.001; hazard ratio for 
TCH, 0.78; P = 0.01) (Table 1A in the Supplemen-
tary Appendix). In addition, a benefit of trastuz-
umab was seen in node-positive patients at high-
est risk for recurrence (i.e., those with ≥4 positive 
nodes), for whom the 5-year rate of disease-free 
survival was 73% in the group receiving AC-T plus 
trastuzumab and 72% in the group receiving TCH, 
as compared with 61% in the group receiving AC-T 
(hazard ratio, 0.66; P = 0.002 for both comparisons) 
(Table 1A in the Supplementary Appendix).
Analysis of the efficacy of trastuzumab on the 
basis of the size of the primary tumor showed 
similarly significant benefits for patients with 
small or large primary tumors, with no significant 
between-group differences among patients with 
tumors of intermediate size (Table 1B in the 
Supplementary Appendix). Among patients with 
HER2-positive tumors measuring 1 cm or less in 
the greatest diameter, the estimated 5-year rates 
of disease-free survival were 86% in the group 
receiving AC-T plus trastuzumab and 86% in the 
group receiving TCH, as compared with 72% in 
the group receiving AC-T (hazard ratio for AC-T 
plus trastuzumab, 0.36; P = 0.03; hazard ratio for 
TCH, 0.45; P = 0.09) (Table 1B in the Supplementary 
Appendix). For tumors measuring 1 cm or more but 
no more than 2 cm, the analysis showed no sig-
nificant difference in 5-year rates of disease-free 
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Figure 1. Disease-free Survival among All Patients 
and According to TOP2A Status.
Shown are the results of Kaplan–Meyer analyses of rel-
ative rates of disease-free survival among all study pa-
tients (Panel A), those without coamplification of the 
gene encoding topoisomerase II alpha (TOP2A) (Panel 
B), and those with coamplification of TOP2A (Panel C). 
AC-T denotes doxorubicin and cyclophosphamide fol-
lowed by docetaxel, and TCH docetaxel, carboplatin, 
and trastuzumab.
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survival, with rates of 87% in the group receiving 
AC-T plus trastuzumab and 86% in the group re-
ceiving TCH, as compared with 86% in the group 
receiving AC-T (hazard ratio for AC-T plus trastuz-
umab, 0.88; P = 0.59; hazard ratio for TCH, 1.11; 
P = 0.64) (Table 1B in the Supplementary Appen-
dix). For tumors measuring 2 cm or more at di-
agnosis, the 5-year rates of disease-free survival 
were 82% in the group receiving AC-T plus tras-
tuz umab and 79% in the group receiving TCH, as 
compared with 71% in the group receiving AC-T 
(hazard ratio for AC-T plus trastuzumab, 0.62; 
P<0.001; hazard ratio for TCH, 0.70; P<0.001) 
(Table 1B in the Supplementary Appendix). Forest-
plot analyses also showed improved efficacy for 
both trastuzumab-containing regimens, as com-
pared with standard therapy, with respect to rates 
of disease-free and overall survival in subgroups 
defined according to nodal status (negative vs. 
positive), hormone-receptor results (negative vs. 
positive), and tumor size (≤2 cm vs. >2 cm) (Fig. 3A 
through 3D in the Supplementary Appendix).
Overall, among the 3222 patients who under-
went randomization, there were only 29 more pri-
mary events in the TCH group (214 events) than 
in the group receiving AC-T plus trastuzumab (185 
events). A comparison of the therapeutic indexes 
of the two trastuzumab-containing regimens and 
the standard-therapy regimen was performed on 
the basis of the numbers of distant breast-cancer 
recurrences, cases of congestive heart failure, and 
cases of acute leukemia occurring in each study 
group (Table 2). In this comparison, the difference 
between the trastuzumab-containing regimens 
was even smaller than the difference in the num-
ber of primary events.
TOP2A Coamplification
Among patients with HER2-positive breast can-
cers without TOP2A coamplification, the disease-
free survival benefit with trastuzumab-containing 
regimens was even greater than that seen in the 
overall analysis of all patients (191 patients in the 
group receiving AC-T, 119 in the group receiving 
AC-T plus trastuzumab, and 130 in the group re-
ceiving TCH) (Fig. 1A and 1B). However, in the 
35% of HER2-positive cancers in which TOP2A was 
coamplified, the rates of disease-free survival for 
the trastuzumab-containing regimens were virtu-
ally indistinguishable from the rate with standard 
therapy (55 patients in the group receiving AC-T, 
52 in the group receiving AC-T plus trastuzumab, 
and 72 in the group receiving TCH) (Fig. 1C). This 
subpopulation of patients appears to derive no in-
cremental benefit from trastuzumab, even though 
the therapeutic index favors TCH over the anthra-
cycline-based regimen because of better short- 
and long-term toxicity profiles (Tables 2, 3, and 4).
Adverse Effects
General Safety
We monitored side effects of the adjuvant chemo-
therapy regimens as well as specific toxic effects 
that were linked to individual agents. All toxic 
effects were graded according to the National Can-
cer Institute Common Toxicity Criteria (version 
2.0). A significant difference favoring the group 
receiving TCH, as compared with the group re-
ceiving AC-T plus trastuzumab, was noted for 
arthralgias, myalgias, the hand–foot syndrome, 
stomatitis, and vomiting (Table 3). Significant dif-
ferences in sensory and motor neuropathies, nail 
changes, and myalgias also favored the TCH group. 
The incidences of neutropenia and leukopenia were 
significantly lower in the TCH group than in the 
group receiving AC-T plus trastuzumab, whereas 
the incidences of anemia and thrombocytopenia 
were significantly lower in the group receiving AC-T 
plus trastuzumab than in the TCH group. Finally, 
acute leukemias developed in seven patients who 
were receiving anthracycline-based regimens and 
in one patient who was receiving TCH. However, in 
this patient, leukemia was diagnosed after the pa-
tient had received an anthracycline for the treat-
ment of a B-cell lymphoma that occurred after her 
breast cancer. None of these patients had a breast-
Table 2. Therapeutic Index for Critical Clinical Events.*
Clinical Event AC-T
AC-T plus 
Trastuzumab TCH
number of events
Total events 201 146 149
Distant breast-cancer recurrence 188 124 144
Grade 3 or 4 congestive heart failure 7 21 4
Acute leukemia 6 1 1†
* This therapeutic index is a compilation of the numbers of distant breast-can-
cer recurrences, cases of congestive heart failure, and cases of acute leuke-
mia. AC-T denotes doxorubicin and cyclophosphamide followed by docetaxel, 
and TCH docetaxel, carboplatin, and trastuzumab.
† This case of acute leukemia developed after the patient received an anthracy-
cline as part of a combination chemotherapy regimen for a diffuse large B-cell 
lymphoma that occurred after she received treatment with TCH for breast 
cancer.
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cancer recurrence, and at the time of this report, 
five of the eight patients with leukemia had died.
Cardiac Safety
At study entry, cardiac risk factors were well bal-
anced among the three study groups (Table 4). At 
the time of this analysis, the incidence of conges-
tive heart failure in the two trastuzumab-contain-
ing regimens was higher in the group receiving 
AC-T plus trastuzumab (2.0%) than in the AC-T 
group (0.7%) or the TCH group (0.4%); the inci-
dence with AC-T plus trastuzumab as compared 
with TCH was increased by a factor of 5. The dif-
ference in rates of congestive heart failure be-
tween the two trastuzumab-containing regimens 
significantly favored TCH over AC-T plus trastuz-
umab (P<0.001). In addition, a significant differ-
ence in sustained, subclinical loss of mean LVEF 
(defined as >10% relative loss) was observed in 
the group receiving AC-T plus trastuzumab, as 
compared with the TCH group (18.6% vs. 9.4%, 
P<0.001), with a rate of 11.2% in the AC-T group. 
Table 3. Adverse Events.*
Event
AC-T
(N = 1050)
AC-T plus 
Trastuzumab 
(N = 1068)
TCH
(N = 1056) P Value†
number of patients (percent)
Grade 3 or 4 nonhematologic events
Arthralgia 34 (3.2) 35 (3.3) 15 (1.4)  0.006
Myalgia 55 (5.2) 56 (5.2) 19 (1.8) <0.001
Fatigue 73 (7.0) 77 (7.2) 76 (7.2) 1.0
Hand–foot syndrome 20 (1.9) 20 (1.9) 0 <0.001
Stomatitis 37 (3.5) 31 (2.9) 15 (1.4) 0.02
Diarrhea 32 (3.0) 60 (5.6) 57 (5.4) 0.85
Nausea 62 (5.9) 61 (5.7) 51 (4.8) 0.38
Vomiting 65 (6.2) 72 (6.7) 37 (3.5) <0.001
Irregular menses 284 (27.0) 260 (24.3) 280 (26.5) 0.25
Specific nonhematologic events
Neuropathy, any grade
Sensory 510 (48.6) 531 (49.7) 380 (36.0) <0.001
Motor 55 (5.2) 67 (6.3) 45 (4.3) 0.04
Nail changes, any grade 518 (49.3) 466 (43.6) 303 (28.7) <0.001
Myalgia, any grade 555 (52.9) 593 (55.5) 411 (38.9) <0.001
Renal failure, any grade 0 0 1 (0.1) 0.50
Grade 3 or 4 creatinine elevation‡ 6 (0.6) 3 (0.3) 1 (0.1) 0.62
Grade 3 or 4 hematologic events
Neutropenia 665 (63.3) 764 (71.5) 696 (65.9) 0.01
Leukopenia 544 (51.8) 644 (60.3) 509 (48.2) <0.001
Febrile neutropenia 98 (9.3) 116 (10.9) 101 (9.6) 0.35
Neutropenic infection 117 (11.1) 127 (11.9) 118 (11.2) 0.63
Anemia 25 (2.4) 33 (3.1) 61 (5.8) <0.001
Thrombocytopenia 17 (1.6) 22 (2.1) 64 (6.1) <0.001
Leukemia 6 (0.6) 1 (0.1) 1 (0.1) 1.0
* AC-T denotes doxorubicin and cyclophosphamide followed by docetaxel, and TCH docetaxel, carboplatin, and trastuzumab.
† P values are for the comparison between the group receiving AC-T plus trastuzumab and the group receiving TCH.
‡ Grade 3 or 4 creatinine elevation was defined according to the National Cancer Institute Common Toxicity Criteria, 
 version 2.0.
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Although the cardiac dysfunction associated with 
trastuzumab after the use of adjuvant anthracy-
clines has been reported to be relatively tran-
sient,22-26 in this study, the subclinical toxic effect 
persisted for several years (Fig. 2). Of 194 of the 
1042 patients (19%) who had a relative reduction 
in LVEF of more than 10% in the group receiving 
AC-T plus trastuzumab, the decrease persisted 
for at least 4 years after randomization in 33% of 
the patients. Of note, 23 of 1073 patients (2.1%) 
who were assigned to receive AC-T plus trastu-
zumab never received trastuzumab because the 
LVEF declined to an unacceptable level after the 
initial anthracycline treatment. Consequently, 
these HER2-positive women received no targeted 
therapy after receiving anthracycline therapy.
Discussion
The rationale supporting the adjuvant use of tras-
tuzumab is derived from an improved understand-
ing of the molecular diversity of human breast 
cancer2,3,21,33 and recognition that this disease 
should not be treated with the one-size-fits-all ap-
proach that has characterized most approaches to 
adjuvant chemotherapy for the past four decades. 
The significant efficacy shown by trastuzumab in 
treating first-line metastatic HER2-positive breast 
cancer21 prompted its evaluation in early-stage dis-
ease. This study is one of four large, randomized 
adjuvant trials undertaken as part of this evalua-
tion. Like the previously reported studies,22-24 our 
study showed improvements in efficacy with the 
adjuvant use of trastuzumab. The major safety 
issue that we observed was increased cardiac dys-
function when trastuzumab was used in combi-
nation with anthracycline-based chemotherapy, 
a finding that is also concordant with the results 
of previous studies.22,23,25,26
Despite these similarities, there are three dis-
tinct differences between our study and the other 
trials of adjuvant trastuzumab. First, we performed 
the intention-to-treat analyses of efficacy and 
safety as originally and prospectively defined in 
the study protocol; no statistical modifications or 
study-group exclusions were permitted for com-
bined or early analyses of data. Second, after the 
initial efficacy results for adjuvant trastuzumab 
were reported in April 2005, only 23 patients 
(2.1%) in the control group (i.e., those receiving 
AC-T) crossed over to receive trastuzumab before 
reaching prespecified study end points. This per-
mitted unbiased long-term comparisons of both 
efficacy and safety among the three study groups. 
Third, and perhaps most important, our study 
was the only one to include a nonanthracycline 
chemotherapy regimen.
Almost all current adjuvant therapies incorpo-
rate the use of anthracyclines on the basis of the 
meta-analysis by the Early Breast Cancer Trialists’ 
Group, which showed an improved efficacy of an-
thracycline-containing chemotherapy regimens 
over regimens without an anthracycline.34 How-
ever, analyses of HER2 status among approxi-
mately 5200 patients who participated in eight 
large, randomized adjuvant trials comparing an-
thracycline with nonanthracycline chemotherapy 
regimens showed that only women with HER2-
positive breast cancer derived an incremental ben-
efit from anthracycline use.35-39 No incremental 
benefit was apparent for the 75 to 80% of breast 
cancers that were HER2-negative. A meta-analysis 
of these and additional data has been reported.40 
Detailed data derived from an analysis of the 
TOP2A gene in our study showed that TOP2A coam-
Table 4. Cardiac Risk Factors and Events.*
Variable
AC-T
(N = 1073)
AC-T plus  
Trastuzumab
(N = 1074)
TCH
(N = 1075)
number of patients (percent)
Risk factors
Diabetes 38 (3.5) 36 (3.4) 28 (2.6)
Hypertension 178 (16.6) 178 (16.6) 190 (17.7)
Obesity† 214 (19.9) 242 (22.5) 234 (21.8)
Hypercholesterolemia 54 (5.0) 47 (4.4) 43 (4.0)
Left-side radiotherapy 378 (35.2) 349 (32.5) 364 (33.9)
Events
Cardiac-related death 0 0 0 
Congestive heart failure‡ 7 (0.7) 21 (2.0) 4 (0.4)§
>10% relative reduction in left 
ventricular ejection fraction¶
114 (11.2)‖ 194 (18.6) 97 (9.4)**
* AC-T denotes doxorubicin and cyclophosphamide followed by docetaxel, and 
TCH docetaxel, carboplatin, and trastuzumab.
† Obesity was defined as a body-mass index (the weight in kilograms divided 
by the square of the height in meters) of 30 or more.
‡ This condition was defined as New York Heart Association grade 3 or 4 con-
gestive heart failure.
§ P<0.001 for the comparison between the group receiving AC-T plus trastuz-
umab and the TCH group.
¶ Results in this category are for 1018 patients receiving AC-T, 1042 patients 
receiving AC-T plus trastuzumab, and 1031 patients receiving TCH.
‖ P<0.001 for the comparison between the group receiving AC-T plus trastuz-
umab and the AC-T group.
** P<0.001 for the comparison between the group receiving AC-T plus trastuz-
umab and the TCH group.
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plification occurred in 35% of HER2-positive pa-
tients and was directly associated with the incre-
mental benefit that anthracyclines provide over 
nonanthracycline regimens in HER2-positive dis-
ease.30 The use of a non-anthracycline (TCH) 
regimen in our study allowed us to ask whether 
preclinical synergies observed between platinum-
based chemotherapy and trastuzumab, as well as 
between docetaxel and trastuzumab,15,27 might 
compensate for the incremental efficacy advan-
tage of anthracyclines in HER2-positive breast 
cancers. Although our study was not powered to 
detect equivalence between the two trastuzumab-
containing groups, outcome data showed that 
TCH had similar efficacy (with respect to disease-
free and overall survival) despite the omission of 
anthracyclines and the use of two rather than 
three cytotoxic drugs. In our study, this phenom-
enon was shown even in patients who are thought 
to be at highest risk for recurrence (i.e., those 
with ≥4 positive lymph nodes or a primary tu-
mor measuring >2 cm at diagnosis). Moreover, 
although the overall numerical advantage (29 
disease-free survival events) in favor of AC-T 
plus trastuzumab over TCH was not significant, 
this difference in efficacy came at the cost of a 
highly significant increase in congestive heart 
failure (21 cases vs. 4 cases). These differences in 
rates of congestive heart failure were not taken 
into account in any of the protocol-specified effi-
cacy comparisons. In addition, our findings show 
that the use of AC-T plus trastuzumab resulted in 
a significantly increased risk of sustained sub-
clinical loss in LVEF. Finally, the use of TCH had 
the pragmatic advantage of allowing patients to 
complete all adjuvant chemotherapy in 12 rather 
than 16 weeks, as well as allowing them to com-
plete 12 months of trastuzumab therapy 12 weeks 
sooner and requiring fewer infusion visits.
The emerging further understanding of long-
term and life-altering toxic effects associated with 
adjuvant anthracyclines may provide the most 
compelling support for nonanthracycline regi-
mens. The well-known, long-term side effects of 
anthracyclines include significantly increased risks 
of congestive heart failure,41,42 myelodysplasia, 
and acute leukemia.43 However, recent analyses 
of the National Cancer Institute Surveillance, Epi-
demiology, and End Results (SEER) database in-
dicate that we may be underestimating the full 
effect of anthracycline use on long-term cardiac 
and hematologic health in patients treated for 
breast cancer with these agents,41-43 possibly be-
cause the majority of adjuvant studies have been 
designed primarily to evaluate differences in ef-
ficacy and have used follow-up periods of 7 to 10 
years for both efficacy and safety analyses. At-
tempts to obtain longer-term safety data, includ-
ing cardiac outcomes, are systematically biased by 
loss of later follow-up.
In addition, the SEER database is derived from 
information on women 65 years of age or older. 
The mean age of women in the HER2-positive 
adjuvant studies was 51 to 52 years, whereas the 
mean age of the overall breast-cancer population 
is approximately 62 years. Given that data from 
our study and other trials22,23,25,26 show that 
trastuzumab augments the incidence of anthracy-
cline-associated congestive heart failure and sub-
clinical loss of LVEF, the full effect of any nons-
ymptomatic damage induced by the combination 
of trastuzumab with anthracycline-based regimens 
may not be apparent until much later as these 
younger women have additional, age-related cardi-
ac insults. Our findings on long-term, subclinical 
LVEF losses, as well as the published results 
from the SEER database analyses,41-43 involving 
some 42,000 women, support this concern.
Furthermore, although myeloid growth fac-
tors permit delivery of full-dose, accelerated-
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Figure 2. Left Ventricular Ejection Fraction (LVEF) at 48 Months.
Shown are the values for the mean left ventricular ejection fraction for 3086 
of 3222 patients (96%) in the three study groups. At the time of this analysis, 
sufficient numbers of LVEF determinations were not yet available beyond 
48 months. AC-T denotes doxorubicin and cyclophosphamide followed by 
docetaxel, and TCH docetaxel, carboplatin, and trastuzumab.
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schedule adjuvant anthracycline–cyclophospha-
mide treatments, registry data suggest a doubling 
of the incidences of acute leukemia and myelo-
dysplasia associated with these regimens, though 
the absolute risk remains low.43 Of note, all cases 
of acute leukemia in our study occurred in pa-
tients who had previously been exposed to an an-
thracycline. Some observers have argued that these 
major toxic effects are rare and are offset by sig-
nificant efficacy gains obtained with anthracy-
clines. However, our data do not fully support this 
argument. We did not find any significant incre-
mental therapeutic benefits of combined trastuz-
umab–anthracycline treatment as compared with 
TCH, yet we did see significant increases in both 
acute and chronic toxic effects with the trastuz-
umab–anthracycline regimen. Consequently, we 
believe that TCH offers an effective alternative 
to the anthracycline-based regimens and their 
associated risks.
An improved understanding of the molecular 
basis of malignant disease is allowing the devel-
opment of rational treatment strategies that are 
more effective and less toxic than traditional 
empiric regimens. The identification and char-
acterization of the HER2 alteration in a subset 
of human breast cancers and the subsequent de-
velopment of trastuzumab represent the practical 
realization of this translational ideal. Our find-
ings show that we can further exploit this new 
translational knowledge to optimize efficacy while 
simultaneously minimizing acute and chronic tox-
ic effects in the adjuvant treatment of HER2-pos-
itive breast cancer.
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